Clinical studies on GLP-1 receptor agonists show that patients may experience significant weight reduction over time, especially when treatment is combined with healthy nutrition and regular physical activity
The decreases previously observed in first-time AOM prescribing in November and December 2024 rebounded in January 2025
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study)
On a COA, check for peptide purity above 95% by HPLC, confirmed copper content, and microbial testing
2020;40:S180-4
These cases are different from asbestos claims, but they share one important idea: companies must take safety concerns seriously and warn people about known risks